Experimental diabetes mellitus exacerbates Tau pathology in a transgenic mouse model of Alzheimer's disease

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Ke, Yazi D ^a   Delerue, Fabien ^a   Gladbach, Amadeus ^a   Götz, Jürgen ^a   Ittner, Lars M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TAU PROTEIN; DRUG DERIVATIVE; FORMIC ACID; FORMIC ACID DERIVATIVE; SARCOSINE; SARKOSYL;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE PREDISPOSITION; INSULIN DEFICIENCY; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; SOLUBILITY; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE; ANIMAL; CHEMISTRY; COMORBIDITY; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; MOUSE; MUTATION; PATHOLOGY; PHOSPHORYLATION; TIME;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; ANIMALS; BLOOD GLUCOSE; COMORBIDITY; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FORMIC ACIDS; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; PHOSPHORYLATION; SARCOSINE; TAU PROTEINS; TIME FACTORS;

EID: 70949084806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007917     Document Type: Article

References (40)

1. Gotz J, Streffer JR, David D, Schild A, Hoerndli F, et al. (2004) Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Mol Psychiatry 9: 664-683.
2. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8: 663-672.
3. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-1159.
4. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, et al. (2007) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114: 5-22.
5. Selkoe DJ (1997) Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275: 630-631.
6. Chen F, David D, Ferrari A, Gotz J (2004) Posttranslational modifications of tau - role in human tauopathies and modeling in transgenic animals. Curr Drug Targets 5: 503-515.
7. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, et al. (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393: 702-705.
8. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, et al. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 95: 7737-7741.
9. Gotz J, Ittner LM (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 9: 532-544.
10. American Diabetes Association (2006) Diagnosis and classification of diabetes mellitus. Diabetes Care 29 Suppl 1: S43-48.
11. Gispen WH, Biessels GJ (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23: 542-549.
12. Gotz J, Ittner LM, Lim YA (2009) Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 66: 1321-1325.
13. Gasparini L, Netzer WJ, Greengard P, Xu H (2002) Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 23: 288-293.
14. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, et al. (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8: 247-268.
15. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, et al. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50: 164-168.
16. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32: 486-510.
17. Hong M, Lee VM (1997) Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272: 19547-19553.
18. Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, Jope RS (2006) Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55: 3320-3325.
19. Planel E, Tatebayashi Y, Miyasaka T, Liu L, Wang L, et al. (2007) Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms. J Neurosci 27: 13635-13648.
20. Gotz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276: 529-534.
21. Deters N, Ittner LM, Gotz J (2008) Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci 28: 137-147.
22. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-1495.
23. Pennanen L, Wolfer DP, Nitsch RM, Gotz J (2006) Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav 5: 369-379.
24. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Gotz J (2003) beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J Biol Chem 278: 40162-40168.
25. Probst A, Gotz J, Wiederhold KH, Tolnay M, Mistl C, et al. (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (Berl) 99: 469-481.
26. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3: 519-526.
27. Ittner LM, Fath T, Ke YD, Bi M, van Eersel J, et al. (2008) Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A 105: 15597-16002.
28. Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, et al. (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86: 3265-3274.
29. Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, et al. (2009) Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol 174: 228-238.
30. Planel E, Bretteville A, Liu L, Virag L, Du AL, et al. (2009) Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J 23: 2595-2604.
31. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, et al. (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol.
32. Frost B, Ollesch J, Wille H, Diamond MI (2009) Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem 284: 3546-3551.
33. Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM (2007) Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A 104: 10252-10257.
34. Rees DA, Alcolado JC (2005) Animal models of diabetes mellitus. Diabet Med 22: 359-370.
35. Ittner LM, Gotz J (2007) Pronuclear injection for the production of transgenic mice. Nat Protoc 2: 1206-1215.
36. David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, et al. (2006) Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 6: 6566-6577.
37. van Eersel J, Bi M, Ke YD, Hodges JR, Xuereb JH, et al. (2009) Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J Neural Transm 116: 1243-1251.
38. Ittner LM, Koller D, Muff R, Fischer JA, Born W (2005) The N-terminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry 44: 5749-5754.
39. Ittner LM, Wurdak H, Schwerdtfeger K, Kunz T, Ille F, et al. (2005) Compound developmental eye disorders following inactivation of TGFbeta signaling in neural-crest stem cells. J Biol 4: 11.
40. Wurdak H, Ittner LM, Lang KS, Leveen P, Suter U, et al. (2005) Inactivation of TGFbeta signaling in neural crest stem cells leads to multiple defects reminiscent of DiGeorge syndrome. Genes Dev 19: 530-535.